Compare Charles River Laboratories Intl. Inc (CRL) vs Gigacloud Technology Inc (GCT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Gigacloud Technology Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while Gigacloud Technology Inc trades at $52.01 (market cap $1.84B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 7.3× Gigacloud Technology Inc's market cap. Which is the better fit depends on your goals.
| CRL | GCT | |
|---|---|---|
Market Cap | $13.46B | $1.84B |
Sector | Health | Technology |
52-Week High | $282.00 | $53.25 |
52-Week Low | $145.57 | $25.44 |
Enterprise Value | $16.30B | $1.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
GigaCloud Technology (GCT) trades at $51.66, up 0.02% on the day, with a bullish technical outlook supported by moving averages and strong support at $50. The company reported Q2 2026 EPS of $1.16, beating estimates, and maintains a 10.65% net income margin. Revenue growth is projected to rise from $1.29B in 2025 to $1.5B in 2026, with consistent profitability.
The stock presents a compelling opportunity with attractive valuations (P/E 12.25, P/S 1.3) and robust fundamentals, though overbought RSI levels near 84 suggest near-term consolidation risk. Analyst consensus is bullish with 67% buy ratings, but investors should monitor execution risks in European expansion and furniture market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →
